查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1712516

全球子宫肌瘤治疗市场 - 2025-2033

Global Uterine Fibroids Treatment Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年全球子宫肌瘤治疗市场规模达15.8亿美元，预计到2033年将达到35.7亿美元，在2025-2033年预测期内的复合年增长率为9.5%。

子宫肌瘤（也称为平滑肌瘤）是由子宫壁内或子宫壁上形成的肌肉和组织构成的生长物。这些肿瘤通常是良性的，是女性最常见的非癌性肿瘤。子宫肌瘤可引起多种症状，如疼痛和大量不规则阴道出血。有时，患者没有任何症状并且不知道自己患有子宫肌瘤。子宫肌瘤的治疗通常取决于症状的严重程度。

子宫肌瘤可以作为单一结节（一次生长）或成簇生长。肌瘤簇的大小范围为直径 1 毫米至 20 公分（8 英吋）以上，甚至更大。相较之下，子宫肌瘤可以小到像种子一样，也可以大到像西瓜一样。这些生长物可以在子宫壁内、子宫主腔或子宫外表面生长。

市场动态：

驾驶员和约束装置

治疗方案的不断进步极大地推动了子宫肌瘤治疗市场的成长。

治疗方案的进步是子宫肌瘤市场成长的主要驱动力之一。这些创新为传统治疗提供了更安全、更有效、微创的替代方法，为患者带来了许多好处，包括缩短恢復时间、降低併发症发生率和改善治疗效果。 Myfembree 和 Yselty 等新药已获批准透过降低导致子宫肌瘤生长的荷尔蒙水平来治疗子宫肌瘤。这些口服药物提供了一种非侵入性的手术替代方法。

例如，2022年8月，Myovant Sciences和辉瑞公司宣布，美国食品药品监督管理局（FDA）批准MYFEMBREE（relugolix 40毫克、雌二醇1毫克、醋酸炔诺酮0.5毫克）作为一粒药、每日一次的疗法，用于治疗绝经前女性子宫内膜异位症相关的时间中度疼痛相关的重度时间。 MYFEMBREE 也被批准用于治疗停经前妇女子宫肌瘤引起的月经过多。

此外，2022 年 6 月，欧盟委员会 (EC) 授予口服 GnRH 拮抗剂 Yselty (linzagolix) 的上市许可，用于治疗育龄成年女性（18 岁以上）的中度至重度子宫肌瘤 (UF) 症状。

认识不足和诊断延迟阻碍了市场成长

认识不足和诊断延迟是阻碍子宫肌瘤治疗市场成长的重要因素。许多女性并不了解这种疾病、其症状以及可用的治疗方法，这常常导致诊断和治疗处于晚期。这给市场成长带来了障碍。

许多女性没有意识到子宫肌瘤的症状，例如月经量大、骨盆腔疼痛和频尿。缺乏认识会导致诊断较晚，通常是在肌瘤变大或治疗变得更加复杂时。例如，根据美国妇产科医师学会的研究表明，多达 60% 的子宫肌瘤女性在出现严重症状之前并不知道自己患有子宫肌瘤。

当诊断出子宫肌瘤时，许多女性可能需要更具侵入性或更复杂的治疗，例如子宫切除术，如果早期干预，这些治疗是可以避免的。如果女性没有及时就医，她们就会错过子宫动脉栓塞术（UAE）或肌瘤切除术等早期治疗的机会，而这些治疗可能侵入性较小，且更有效地保护生育能力和整体健康。

目录

第一章：市场介绍和范围

  • 报告目标
  • 报告范围和定义
  • 报告范围

第二章：高阶主管见解与关键要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按类型分类的程式码片段
  • 治疗片段
  • 按地区分类的片段

第三章：动态

  • 影响因素
    • 驱动程式
      • 治疗方案不断进步
      • 荷尔蒙疗法的发展
    • 限制
      • 认知有限，诊断延迟
      • 与治疗相关的副作用
    • 机会
      • 专注于保留生育能力的治疗
    • 影响分析

第四章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大行销品牌的既定领导者
    • 拥有成熟产品的市场领导者
  • 最新进展与突破
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第五章：子宫肌瘤治疗市场（按类型）

  • 壁内肌瘤
  • 黏膜下肌瘤
  • 浆膜下肌瘤
  • 带蒂子宫肌瘤

第六章：子宫肌瘤治疗市场（依治疗方法）

  • 荷尔蒙疗法
    • 醋酸亮丙瑞林
    • 雌二醇
    • 醋酸炔诺酮
    • 其他的
  • 促性腺激素释放激素（GnRH）拮抗剂
    • 恶拉戈利克斯
    • 瑞卢戈利克斯
    • 林札戈利克斯
  • GnRH激动剂
    • 那法瑞林
    • 布舍瑞林
    • 曲普瑞林
    • 其他的
  • 黄体素
    • 醋酸甲羟孕酮
    • 醋酸甲地孕酮
  • 选择性孕酮受体调节剂（SPRM）
    • 米非司酮
    • 乌利司他
    • 特拉司酮
    • 奥那司酮
    • 其他的
  • 手术治疗
    • 肌瘤切除术
    • 子宫切除术
    • 子宫肌瘤栓塞术
    • 射频消融
    • 子宫内膜消融术

第七章：子宫肌瘤治疗市场，依区域市场分析与成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第八章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的关键发展
  • 公司基准化分析

第九章：公司简介

  • AbbVie Inc.
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 关键进展
      • 併购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT分析
  • Pfizer Inc.
  • AstraZeneca
  • Kissei Pharmaceutical Co., Ltd.
  • Theramex

第十章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 11 章：附录

简介目录
Product Code: PH8

The global uterine fibroids treatment market size reached US$ 1.58 billion in 2024 and is expected to reach US$ 3.57 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033.

Uterine fibroids (also called leiomyomas) are growths made of muscle and tissue that form in or on the wall of the uterus. These growths are usually benign and are the most common noncancerous tumors in females. Uterine fibroids can cause a variety of symptoms like pain and heavy, irregular vaginal bleeding. Sometimes, a person has no symptoms and is unaware they have fibroids. Treatment for fibroids typically depends on the severity of the symptoms.

Fibroids can grow as a single nodule (one growth) or in a cluster. Clusters of fibroids can range in size from 1 millimeter to more than 20 centimeters (8 inches) in diameter or even larger. For comparison, fibroids can be as small as a seed or as large as a watermelon. These growths can develop within the wall of the uterus, inside the main cavity of the uterus, or on the outer surface of the uterus.

Market Dynamics: Drivers & Restraints

Rising advancements in treatment options are significantly driving the uterine fibroids treatment market growth.

Advancements in treatment options are one of the key drivers of growth in the uterine fibroids market. These innovations offer safer, more effective, and minimally invasive alternatives to traditional treatments, providing numerous benefits for patients, including reduced recovery time, lower complication rates, and better outcomes. New drugs like Myfembree and Yselty have been approved to treat fibroids by reducing the hormone levels that contribute to fibroid growth. These oral medications provide a non-invasive alternative to surgery.

For instance, in August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill, once-a-day therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. MYFEMBREE is also approved for heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Additionally, in June 2022, the European Commission (EC) granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Limited awareness and delayed diagnosis hamper the market growth

Limited awareness and delayed diagnosis are significant factors that hamper the growth of the uterine fibroids treatment market. Many women are unaware of the condition, its symptoms, and available treatments, which often leads to late-stage diagnosis and treatment. This creates barriers to market growth.

Many women do not recognize the symptoms of uterine fibroids, such as heavy menstrual bleeding, pelvic pain, and frequent urination. This lack of awareness results in late diagnosis, often when the fibroids have grown larger or become more complicated to treat. For instance, according to the American College of Obstetricians and Gynecologists, studies suggest that up to 60% of women with uterine fibroids are unaware that they have them until they experience severe symptoms.

By the time fibroids are diagnosed, many women may require more invasive or complex treatments, such as a hysterectomy, which could have been avoided with earlier intervention. When women do not seek medical advice on time, they miss the opportunity for early-stage treatments like uterine artery embolization (UAE) or myomectomy, which could be less invasive and more effective in preserving fertility and overall health.

Segment Analysis

The global uterine fibroids treatment market is segmented based on type, treatment, and region.

Treatment:

The surgical treatment segment is expected to dominate the uterine fibroids treatment market with the highest market share.

Surgical treatment remains an effective treatment for uterine fibroids, primarily due to its high efficacy in completely removing fibroids, providing long-term relief from symptoms, and widespread availability. The best treatment for uterine fibroids depends on individual factors, but options range from medication to surgery, with myomectomy (surgical removal of fibroids) being a common choice for those wanting to preserve their uterus, and hysterectomy (removal of the uterus) for those who don't want to get pregnant in the future.

The only permanent solution for uterine fibroids, that it eliminates the possibility of fibroid recurrence. Recommended for women experiencing severe symptoms (e.g., heavy menstrual bleeding, chronic pelvic pain) who do not plan to conceive. For instance, the National Uterine Fibroids Foundation states that a hysterectomy is performed in 30-40% of fibroid cases due to its definitive nature. Over 200,000 hysterectomies are performed annually in the U.S. due to fibroids, making it one of the most common surgical procedures among women.

Geographical Analysis

North America is expected to hold a significant position in the global uterine fibroids treatment market with the highest market share

Uterine fibroids affect 60-80% of women of reproductive age, and the condition is particularly prevalent among African American women, with studies showing that African American women are 2-3 times more likely to develop fibroids compared to Caucasian women. For instance, according to the Centers for Disease Control and Prevention (CDC), uterine fibroids are one of the most common reasons for hysterectomies in the United States, with about 200,000 surgeries performed annually for fibroids. In the United States, nearly 1 in 5 women are affected by uterine fibroids during their lifetime, driving high demand for treatment options.

North America benefits from some of the best healthcare facilities in the world, including specialized centers for gynecology and women's health, which are equipped with state-of-the-art medical technologies for diagnosing and treating uterine fibroids. For instance, the Cleveland Clinic, Johns Hopkins Medicine, and other prominent hospitals offer minimally invasive surgeries like robotic-assisted myomectomy and MRI-guided Focused Ultrasound (MRgFUSl), positioning the region at the forefront of fibroid treatment innovation.

There has been a growing focus on women's reproductive health in North America, resulting in increased awareness about uterine fibroids and their associated symptoms, including heavy bleeding, pelvic pain, and infertility. This has led to more women seeking medical care and treatment options. For instance, in 2021, the Fibroid Foundation in the U.S. conducted awareness campaigns that helped highlight the impacts of uterine fibroids, raising awareness among women and encouraging early diagnosis and treatment.

Competitive Landscape

Top companies in the uterine fibroids treatment market include AbbVie Inc., Pfizer Inc., AstraZeneca, Kissei Pharmaceutical Co., Ltd., and Theramex, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global uterine fibroids treatment market report delivers a detailed analysis with 39 key tables, more than 41 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Treatment
  • 2.5. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Treatment Options
      • 3.1.1.2. Development of Hormonal Therapies
    • 3.1.2. Restraints
      • 3.1.2.1. Limited Awareness and Delayed Diagnosis
      • 3.1.2.2. Side Effects Associated with the Treatments
    • 3.1.3. Opportunity
      • 3.1.3.1. Focus on Fertility-Preserving Treatments
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics
  • 4.12. Key Opinion Leaders

5. Uterine Fibroids Treatment Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Intramural Fibroids*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Submucosal Fibroids
  • 5.4. Subserosal Fibroids
  • 5.5. Pedunculated Fibroids

6. Uterine Fibroids Treatment Market, By Treatment

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 6.1.2. Market Attractiveness Index, By Treatment
  • 6.2. Hormone Therapy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Leuprolide Acetate
    • 6.2.4. Estradiol
    • 6.2.5. Norethindrone Acetate
    • 6.2.6. Others
  • 6.3. Gonadotropin-Releasing Hormone (GnRH) Antagonists
    • 6.3.1. Elagolix
    • 6.3.2. Relugolix
    • 6.3.3. Linzagolix
  • 6.4. GnRH Agonists
    • 6.4.1. Nafarelin
    • 6.4.2. Buserelin
    • 6.4.3. Triptorelin
    • 6.4.4. Others
  • 6.5. Progestins
    • 6.5.1. Medroxyprogesterone Acetate
    • 6.5.2. Megestrol Acetate
  • 6.6. Selective Progesterone Receptor Modulators (SPRMs)
    • 6.6.1. Mifepristone
    • 6.6.2. Ulipristal
    • 6.6.3. Telapristone
    • 6.6.4. Onapristone
    • 6.6.5. Others
  • 6.7. Surgical Treatment
    • 6.7.1. Myomectomy
    • 6.7.2. Hysterectomy
    • 6.7.3. Uterine Fibroid Embolization
    • 6.7.4. Radiofrequency Ablation
    • 6.7.5. Endometrial Ablation

7. Uterine Fibroids Treatment Market, By Regional Market Analysis and Growth Opportunities

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 7.1.2. Market Attractiveness Index, By Region
  • 7.2. North America
    • 7.2.1. Introduction
    • 7.2.2. Key Region-Specific Dynamics
    • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.2.5.1. U.S.
      • 7.2.5.2. Canada
      • 7.2.5.3. Mexico
  • 7.3. Europe
    • 7.3.1. Introduction
    • 7.3.2. Key Region-Specific Dynamics
    • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.3.5.1. Germany
      • 7.3.5.2. UK
      • 7.3.5.3. France
      • 7.3.5.4. Spain
      • 7.3.5.5. Italy
      • 7.3.5.6. Rest of Europe
  • 7.4. South America
    • 7.4.1. Introduction
    • 7.4.2. Key Region-Specific Dynamics
    • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.4.5.1. Brazil
      • 7.4.5.2. Argentina
      • 7.4.5.3. Rest of South America
  • 7.5. Asia-Pacific
    • 7.5.1. Introduction
    • 7.5.2. Key Region-Specific Dynamics
    • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 7.5.5.1. China
      • 7.5.5.2. India
      • 7.5.5.3. Japan
      • 7.5.5.4. South Korea
      • 7.5.5.5. Rest of Asia-Pacific
  • 7.6. Middle East and Africa
    • 7.6.1. Introduction
    • 7.6.2. Key Region-Specific Dynamics
    • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

8. Competitive Landscape and Market Positioning

  • 8.1. Competitive Overview and Key Market Players
  • 8.2. Market Share Analysis and Positioning Matrix
  • 8.3. Strategic Partnerships, Mergers & Acquisitions
  • 8.4. Key Developments in Product Portfolios and Innovations
  • 8.5. Company Benchmarking

9. Company Profiles

  • 9.1. AbbVie Inc.*
    • 9.1.1. Company Overview
    • 9.1.2. Product Portfolio
      • 9.1.2.1. Product Description
      • 9.1.2.2. Product Key Performance Indicators (KPIs)
      • 9.1.2.3. Historic and Forecasted Product Sales
      • 9.1.2.4. Product Sales Volume
    • 9.1.3. Financial Overview
      • 9.1.3.1. Company Revenue
      • 9.1.3.2. Geographical Revenue Shares
      • 9.1.3.3. Revenue Forecasts
    • 9.1.4. Key Developments
      • 9.1.4.1. Mergers & Acquisitions
      • 9.1.4.2. Key Product Development Activities
      • 9.1.4.3. Regulatory Approvals, etc.
    • 9.1.5. SWOT Analysis
  • 9.2. Pfizer Inc.
  • 9.3. AstraZeneca
  • 9.4. Kissei Pharmaceutical Co., Ltd.
  • 9.5. Theramex

LIST NOT EXHAUSTIVE

10. Assumption and Research Methodology

  • 10.1. Data Collection Methods
  • 10.2. Data Triangulation
  • 10.3. Forecasting Techniques
  • 10.4. Data Verification and Validation

11. Appendix

  • 11.1. About Us and Services
  • 11.2. Contact Us